TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06329024

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Both groups are given rehabilitation treatment. The main intervention measures included: 1) non-invasive ventilator treatment, generally at least once every night and typically not exceeding continuous daily usage.; 2) attention to feeding and sleeping positions, with a recommended sleeping position of lateral recumbent and the head of the bed raised by 20-30°; 3) swallowing function training, such as tongue muscle stretching training, assisted anterior jaw protrusion training, lemon ice stimulation to the soft palate, pharyngeal wall, etc., generally 5 days per week, twice per day, 5-20 minutes each time; 4) pulmonary ultrashort wave therapy, generally at least 2-3 times a week, and not more than once a day; 5) physical therapy, such as intensive training for gross motor functions including lifting the head, turning over, sitting, crawling, standing, etc., generally 3-5 days per week, 1-2 times per day, 5-20 min each time.
Study: NCT05534230

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intravenous normal saline at a standard dose of 0.5mcg/kg/hr continued to postop until extubation.
Study: NCT04828174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-TRBC1 CAR-T cell therapy
Description: TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
Study: NCT06462248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUCART19
Description: anti-CD19 chimeric antigen receptor modified T-cell (CAR-T)
Study: NCT06329024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Myofascial Release Therapy
Description: Myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. It involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. Myofascial release therapy is commonly used to treat muscle spasms, chronic pain, skeletal and joint issues, among others.
Study: NCT06011707

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPT-IN
Description: Parents will be provided with online access to 6 compulsory video-based modules and 8 optional video-based modules. These modules will teach them about child development, behavioural principles, and naturalistic developmental intervention principles. These modules will promote skills that parents can use to increase their child's social and communication behaviours and minimize behaviours that interfere with learning (e.g., temper tantrums).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational control
Description: This control intervention will provide parents with 6 compulsory and 8 optional modules that will teach them about autism and its developmental course.
Study: NCT06257251

Intervention type: OTHER
Intervention: Histological slides digitization
Description: Histological slides of the capsule samples taken during surgery will be collected for analysis and digitized. Using the NDPview2 software, the investigators will manually count the silicone particles present in the peri-prosthetic capsule and measure the surface area of the capsule to estimate the silicone particle density.
Study: NCT05411341

Intervention type: DEVICE
Intervention: Argos (Alcon Laboratories, Inc.)
Description: An ocular biometry examination will be performed on the affected eyes using the Argos device.

Intervention type: DEVICE
Intervention: IOLMaster 500 (Carl Zeiss Meditec AG)
Description: An ocular biometry examination will be performed on the affected eyes using the IOL Master 500 device.
Study: NCT01024257

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: beta-irradiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conjunctival autograft
Study: NCT06540989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate treatment
Description: Participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deferred treatment
Description: This group of participants will receive the same treatment as those in the immediate treatment group. The only difference is the timeline of treatment onset. Therefore, participants will access a web-based app using their phone to record 100 sentences every treatment session. Noise-augmented feedback will be provided to increase accuracy of speech productions.
Study: NCT05293678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (IV)
Description: Administered in single intravenous (IV) dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (IV)
Description: Administered in single intravenous (IV) dose
Study: NCT05352555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated vertigo repositioning chair
Description: Patients are strapped to the chair with a safety harness, and video fenzel goggle are worn.~Automated diagnostic procedures are performed to determine vertigo subtype and orientation (Left/Right) (described below).~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll (for horizontal canal involvement)~3. (Optional) Deep Head Hanging (for anterior canal involvement)~If nystagmus is detected during automated diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding automated treatment maneuver will be performed (described below).~1. Epley's and/or Semont's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~3. Yacovino's maneuver (for anterior canal involvement)~10 minutes after performing automated treatment maneuver, provocative diagnostic test maneuver was performed once again to ensure successful intervention.~A follow-up was done one week later at the earliest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Canalith Reposition Maneuver
Description: Patients were seated on a examination table and given videonystagmography goggles (VNG).~Manual diagnostic procedures are performed to determine vertigo subtype and orientation.~The manual diagnostic procedures for Left and Right sided semicircular canals are:~1. Dix-Hallpike (for posterior canal involvement)~2. Supine roll and Bow and Lean (for horizontal canal involvement)~If nystagmus is detected during diagnostic maneuvers, BPPV subtype is diagnosed, and corresponding treatment maneuvers will be performed manually.~The automated treatment maneuvers are:~1. Epley's maneuver (for posterior canal involvement)~2. Barbecue and/or Gufoni's maneuver (for horizontal canal involvement)~Patients were called back for a follow up 2 days after performing manual treatment maneuvers. Provocative diagnostic testing maneuvers were performed again to ensure successful intervention.~A second follow-up was done one week later at the earliest.
Study: NCT05990556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional procedure to block bilateral meningeal blood supply
Description: The embolic agent used in bilateral meningeal blood supply occlusion through interventional surgery is Onyx glue (liquid embolic system). After the location of bilateral middle meningeal artery was determined by femoral artery puncture angiography, SL-10 was sent to the opening of bilateral middle meningeal artery through guiding catheter, and Onxy glue was used to block the bilateral middle meningeal artery. The standard of embolization was that the middle meningeal artery was not seen and Onyx glue was not diffused to the petrous branch of the middle meningeal artery. In order to avoid dangerous anastomotic branches and complications, attention should be paid to superselecting the middle meningeal artery and slowly injecting Onyx glue during the operation. After embolization of the middle meningeal artery by interventional surgery, glioblastoma was removed immediately under the guidance of multimodal imaging.
Study: NCT05293678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (IV)
Description: Administered in single intravenous (IV) dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (IV)
Description: Administered in single intravenous (IV) dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (IV)
Description: Administered in single IV dose
Study: NCT05165420

Intervention type: OTHER
Intervention: Cosmetic product
Description: RV4941A is a face cream product
Study: NCT05293678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (IV)
Description: Administered in single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (IV)
Description: Administered in single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (IV)
Description: Administered in single IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (SC)
Description: Administered in single subcutaneous (SC) dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (SC)
Description: Administered in single subcutaneous (SC) dose
Study: NCT06034977

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADI-PEG20
Description: Lenvatinib + ADI-PEG20 combination treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG20
Description: Lenvatinib + ADI-PEG20 combination treatment.
Study: NCT05390710

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: LAE005 + Afuresertib + Nab-Paclitaxel
Description: LAE005: 1200 mg IV Q3W, Afuresertib: 125 mg QD, Nab paclitaxel:125 mg/m D1, D8 Q3W
Study: NCT05293678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN15160 (SC)
Description: Administered in single subcutaneous (SC) dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (SC)
Description: Administered in single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (SC)
Description: Administered in single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (SC)
Description: Administered in single SC dose
Study: NCT05912049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3811 Injection
Description: Single dose intravenously infused on day 1
Study: NCT06229054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (DEX), an α2-agonist with more promising pharmacokinetic and pharmacodynamic characteristics than clonidine has been proved to have a positive effect on postoperative pain intensity and to reduce opioid consumption

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: local anesthesic which works through blocking sodium channels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: local anesthesic which works through blocking sodium channels
Study: NCT05095415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Pre-operative Consult
Description: Preoperative education will be given by the treating orthopedic surgeon first and will then be followed by a consult with a final semester, occupational therapy student. The pre-operative education will include the importance of attending therapy, what to expect at therapy, typical duration of therapy for their specific diagnosis, and address any questions of ther participant. Participants will be given educational materials and access to education videos to watch if they so choose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Typical Pre-Operative Education
Description: Participants will receive all preoperative education from their orthopedic surgeon and will not be spoken to directly about the therapeutic process until their first scheduled therapy appointment.
Study: NCT06213181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: It consists of 8 weekly sessions with a duration of 2 hours each. A variety of mindfulness practices including mindful movement will be introduced in all sessions. Participants will approach meditation as something natural and everyday, with the possibility of directing attention in all the moments and activities of daily life. Body scanning practices and conscious breathing will also be included. We will work in the group, with reflections and readings, as well as carrying out meditation and mindfulness practices, during the week, so that they can be carried out in the daily life of each participant. The intervention based on mindfulness will focus on the areas of well-being and personal skills such as attention, communication, emotional regulation and decision making.
Study: NCT05912049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching placebo intravenously infused on day 1
Study: NCT05728281

Intervention type: OTHER
Group type: OTHER
Intervention: Recommended time after hysterectomy
Description: Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.

Intervention type: OTHER
Group type: OTHER
Intervention: Recommended time after hysterectomy
Description: Currently there is no consensus on the optimal time to resume sexual activity. Using a randomization, we will therefore compare two groups: one, whose postoperative instructions will indicate a resumption of sexual activity from 4 weeks after the operation and the other from 8 weeks postoperatively. The primary endpoint is the FSFI® score. The patients will answer the FSFI® questionnaire preoperatively and then at 3 months after surgery.
Study: NCT05265507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Description: Glycopyrronium (0.2mg) was intravenously given at the ending of the surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Glycopyrronium (4mg) was intravenously given at the ending of the surgery.
Study: NCT06289543

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative carbohydrate solution
Description: water and solution will be given to patients to drink 2 hours before the operation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative carbohydrate solution
Description: water and solution will be given to patients to drink 2 hours before the operation
Study: NCT04874129

Intervention type: DRUG
Group type: OTHER
Intervention: YYC506-T and YYC506-A (phase 1)
Description: Comparator

Intervention type: DRUG
Group type: OTHER
Intervention: YYC506 (phase 1)
Description: Test

Intervention type: DRUG
Group type: OTHER
Intervention: YYC506-T and YYC506-A (phase 2)
Description: Comparator

Intervention type: DRUG
Group type: OTHER
Intervention: YYC506 (phase 2)
Description: Test
Study: NCT05387057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame training according to the 'Brain-IT' exergame-based training concept
Description: For an overview, our 'Brain-IT' exergame-based training concept consists of an individually adapted multi-domain exergame-based simultaneous cognitive-motor training with incorporated cognitive tasks that will be adopted with a deficit-oriented focus on the neurocognitive domains of (1) learning and memory, (2) executive function, (3) complex attention, and (4) visuospatial skills. According to the training concept, each participant is instructed to train 5x/week for 24 min per session resulting in a weekly exercise volume of 120 min. All training sessions are planned to take place at participant's homes using the exergame training system 'Senso Flex' (Dividat AG, Schindellegi, Switzerland). For a detailed description of the complete 'Brain-IT' exergame-based training concept with sufficient details to allow full replication, consider our methodological paper (doi: 10.3389/fnagi.2021.734012).
Study: NCT05869513

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable oil
Description: Mixed vegetable oil

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Krill oil
Description: Superba Krill Oil

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based resistance exercise
Description: Home based resistance band and body weight exercise

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Home-based resistance exercise
Description: Home based resistance band and body weight exercise
Study: NCT06205212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-flow nasal oxygen
Description: preoxygenation using high-flow nasal oxygen, FiO2 1.0, 40 L/min, 3 min

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: facemask
Description: preoxygenation using facemask, FIO2 1.0, fresh gas flow 10 L/min, 3 min
Study: NCT05387057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The control group will proceed with usual care as provided by the (memory) clinics where the patients are recruited.
Study: NCT05977777

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast- enhanced ultrasound
Description: Contrast- enahnched ultrasound is performed on target pancreatic lesion
Study: NCT05088668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented reality
Description: The subjects will perform scapular repositioning exercise using glasses of augmented reality to see their scapular movement simultaneously. Furthermore, they will also see at the same time a video record of an ideal scapular movement, and will me encouraged to simulate that ideal scapular movement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular repositioning exercise
Description: Subjects will perform scapular repositioning exercises for improving scapular movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Scapular repositioning exercise
Description: Subjects will perform scapular repositioning exercises for improving scapular movement.
Study: NCT06504186

Intervention type: DRUG
Group type: OTHER
Intervention: Blinatumomab
Description: * Ph-negative B-ALL: bephedolumab (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.~* Ph-positive B-ALL: treatment with bephytoin + TKIs, bephytoin (≥ 45 kg: 9 mcg/d D1-2, 28 mcg/d D3-14 or 28 mcg/d D1-14; \< 45 kg: 5 mg/m2/d D1-2, 15 mg/m2/d D3-14) in 28-day cycles for 3 cycles.
Study: NCT06502938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pan-vascular interventional robotic system
Description: Pan-vascular interventional robotic system assited PCI for delivery and manipulation of guidewires, catheters, and quick exchange balloon dilatation catheters/stents.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional artificial percutaneous coronary intervention
Description: Doctors perform traditional percutaneous coronary intervention
Study: NCT06001619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostate hyperplasia medication
Description: The dosages prostatic hyperplasia medication: dutasteride 0,5 MG x1 or finasteride 5 MG x1 or combination of dutasteride and tamsulosin 0,5/0,4 MG x1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LhRH-antagonist
Description: The starting dose in prostatic cancer patient cohort of LHRH antagonist degarelix is 120 MGx2 and the maintenance dose is 80 MGx1.
Study: NCT05367128

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual task training
Description: All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual task training
Description: All participants will receive cognitive dual task training for 30 min/session, 2-3 sessions/week for 4-6 weeks (a total of 12 sessions). The cognitive dual task training includes 15 min of cognitive task combining with standing task and 15 min of cognitive task combining with walking task. The differences among group are the instructions of task prioritization given by the therapist
Study: NCT06359912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPCs
Description: IV

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical standard treatment (CST)
Description: Clinical standard treatment

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinical standard treatment (CST)
Description: Clinical standard treatment